Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-424-8 | CAS number: 947-04-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 was 2,330 mg/kg bw (rat) with central nervous system stimulation (trembling, convulsive twitches, ataxia) as the main clinical sign appearing at about 1,580 mg/kg bw. The dermal LD50 was greater than 2,000 mg/kg bw (rat). Decreased food consumption and stagnation of body weight development were noted. Valid acute inhalation studies in rats are not avail
Among the existing valid studies following three studies were found to show the highest toxicity after oral, dermal and inhalativ application of isophorone: The acute toxicity in laboratory animals is low to moderate with an oral LD50 (rat) of 1500 mg/kg bw (Günzel and Richter, Schering AG, 1968), a dermal LD50 (rabbit) of 1200 mg/kg bw (Dutertre-Catella, 1976) and an inhalative LC50 (rat, aerosol) of 7000 mg/m3 air (Esso Research, 1965).
Among the existing valid studies following three studies were found to show the highest toxicity after oral, dermal and inhalativ application of isophorone: The acute toxicity in laboratory animals is low to moderate with an oral LD50 (rat) of 1500 mg/kg bw (Günzel and Richter, Schering AG, 1968), a dermal LD50 (rabbit) of 1200 mg/kg bw (Dutertre-Catella, 1976) and an inhalative LC50 (rat, aerosol) of 7000 mg/m3 air (Esso Research, 1965).
Among the existing valid studies following three studies were found to show the highest toxicity after oral, dermal and inhalativ application of isophorone: The acute toxicity in laboratory animals is low to moderate with an oral LD50 (rat) of 1500 mg/kg bw (Günzel and Richter, Schering AG, 1968), a dermal LD50 (rabbit) of 1200 mg/kg bw (Dutertre-Catella, 1976) and an inhalative LC50 (rat, aerosol) of 7000 mg/m3 air (Esso Research, 1965).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1985-01-09 - 1985-01-29
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- 1981
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Strain: Wistar (Bor: WISW (SPF TNO))
- Source: Winkelmann, Borchen (Germany)
- Weight at study initiation:
females 117 g, males 126 g (mean) environmental conditions: Feed: R 10 complete feed for rats (Ssniff, Soest; Germany); Water: tap water ad libitum; Room temperature: 20°C (+/- 1°C); Humidity: 60% (+/- 5%), Air change: 15 times per hour; illumination: 12 hour light/dark rhythm - Route of administration:
- oral: gavage
- Vehicle:
- other: fatty alcohol ethoxylate (Cremophor EL)
- Details on oral exposure:
- - Test substance preparation: the test substance was finely ground in a mortar, mixed with cremophor EL, stirred in an Ultra-Turrax and then heated to 40 °C.
- Single dose after 16 h of fasting
- Volume administered or concentration: 20 ml/kg - Doses:
- - Doses: 1580 / 1990 / 2510 / 3160 mg/kg bw (gavage),
selected after screening test with small number of animals - No. of animals per sex per dose:
- 5; highest dose: 10
- Control animals:
- no
- Details on study design:
- - Post dose observation period: 14 days
EXAMINATIONS:
- body weight: before and on days 1, 7, 14 after treatment
- clinical signs: up to 6 hours after treatment, then daily
- gross pathology at the end of investigation - Statistics:
- Litchfield and Wilcoxon (1949), J. Pharmacol. Exp. Ther. 96, 99
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 330 mg/kg bw
- 95% CL:
- 2 044 - 2 656
- Mortality:
- 1580 mg/kg: none
1990 mg/kg: 3 males, 1 female, within 24 hours
2510 mg/kg: 1 male, 5 females, within 24 hours
3160 mg/kg: 8 males, 7 females, within 72 hours - Clinical signs:
- other: Observed in all dosed animals: About 10 to 15 minutes after adminstration, the animals took a prone position and showed convulsive twitches, tremor and Straub's phenomenon. After half an hour, the animals took a lateral position, had a ruffled fur and con
- Gross pathology:
- Post-mortem dissection revealed hyperaemia of the gastric and intestinal mucosae, hyperaemia of the lungs, light-coloured spots on the liver and liver congestion. Dissection at the end of the experiment also revealed hyperaemia of the gastric and intestinal mucosae in some animals.
- Other findings:
- no further information
- Conclusions:
- In a determination of the acute oral toxicity on male and female rats it was found that the LD50 of the test item Dodecane-12-lactam (lauryl lactame) is 2330 mg/kg of body weight. Under the conditions of this study the acute toxicity of Dodecane-12-lactam (lauryl lactame) afer oral application in rats is very low.
- Executive summary:
In a determination of the acute oral toxicity on male and female rats it was found that the LD50 of the test item Dodecane-12-lactam (lauryl lactame) is 2330 mg/kg of body weight. In few cases, the treated animals showed signs of toxicity during the 14 day observation period. There was no influence on the increase in body weight. Dissection at the end of the experiment revealed hyperaemia of the gastric and intestinal mucosae in some animals.
Under the conditions of this study the acute toxicity of Dodecane-12-lactam (lauryl lactame) after oral application in rats is very low.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 330 mg/kg bw
- Quality of whole database:
- Klimisch 1 (reliable without restrictions)
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: limited documentation
- Principles of method if other than guideline:
- see "Details on dermal exposure" and "Details on study design"
- GLP compliance:
- no
- Test type:
- other: single dose was used
- Limit test:
- yes
- Specific details on test material used for the study:
- Lauryl lactam supplied by Elf Atochem, purity not stated
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Weight at study initiation:
- 5 male and 5 female rats, supplied from IFFA-CREDO
325-374 g, mean 356 g (males)
220-270 g, mean 236 g (females)
- Controls: untreated. No details reported. - Type of coverage:
- occlusive
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on dermal exposure:
- - test substance preparation: the test substance was ground to fine powder and suspended in 1% aqueous carboxy methyl cellulose
- to the shaved back of the animals
- Occlusion: yes, for 24 hours
- Vehicle: 1 % carboxy methylcellulose (CMC) aqueous suspension
- Concentration in vehicle: 40 %
- Total volume applied: 5 ml/kg bw
- Removal of test substance: yes, washed off with lukewarm water 24 hours after administration. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- EXAMINATIONS:
- clinical observations after end of exposure,
repeated during next hours, and
repeated daily for 14 days
- autopsy after 14 days observation period. - Statistics:
- no data
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- no mortalities
- Clinical signs:
- other: Slight decrease in food comsumption (no quantitative data presented)
- Gross pathology:
- No findings
- Other findings:
- IRRITATION: no skin effects at all were noted.
- Conclusions:
- In a determination of the acute dermal toxicity on male and female rats it was found that the LD50 of the test item Dodecane-12-lactam (lauryl lactame) is above 2000 mg/kg of body weight. Under the conditions of this study the acute toxicity of Dodecane-12-lactam (lauryl lactame) afer dermal application in rats is very low.
- Executive summary:
The test item Dodecane-12 -lactam (lauryl lactame) was applicated at the skin of the male and female rats in a dose of 2000 mg/kg body weight. No mortalities were observed at this dose. Hence the LD50 of the acute dermal toxicity on male and female rats is above 2000 mg/kg of body weight for the test item Dodecane-12-lactam (lauryl lactame) in rats.
Under the conditions of this study the acute toxicity of Dodecane-12-lactam (lauryl lactame) afer dermal application in rats is very low.
Reference
no further remarks
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Klimisch 2 (reliable with restrictions)
Additional information
Studies in Animals
Dermal
In a limit test with rats, no mortality occurred after dermal treatment with 2000 mg/kg bw for 24 hours under occlusive conditions. The treatment did not produce any adverse skin effects and clinical signs were limited to a slight decrease in food consumption and stagnation of body weight development, which also might have been caused by the constraints of the occlusive treatment. No abnormalities were observed at necropsy (Centre de Recherche et d'Elevage des Oncins, 1975).
Oral
After oral application the LD50 for rats was found to be 2330 mg/kg bw in a test performed according to OECD TG 401 (1981) at dose levels of 1580, 1990, 2510, and 3160 mg/kg bw. Clinical signs observed at doses ≥ 1580 mg/kg bw included prone position, convulsive twitches, tremor and impairment of breathing, followed by sedation and ataxia, salivation, hypothermia, staggering, crouched posture, and closed or small dark eyes. After 2 - 3 days, the animals showed an increase in motility and, in part, vocalization when being touched. Signs of toxicity disappeared after 11 days in the animals dosed with up to 2510 mg/kg bw. Necropsy findings of animals that died during the study revealed hyperaemia of the gastric and intestinal mucosae, hyperaemia of the lungs, light-coloured spots on the liver and liver congestion. Hyperaemia of the gastric and intestinal mucosae were also found in some animals necropsied at the end of the study (Hüls AG, 1985). In a further study the LD50 for rats was determined to be 2600 mg/kg bw ( Centre de Recherche et d'Elevage des Oncins, 1975).
Inhalation
Valid acute inhalation studies are not available.
Studies in Humans
No information is available regarding dermal, inhalation and oral acute toxicity.
Justification for classification or non-classification
According to the criteria of EC Directive 67/548/EEC and EC Regulation 1272/2008 and based on the results of the studies Dodecane-12-lactam is not classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.